Glofitamab Shows 75% Response Rate in Refractory CNS Lymphoma

Therapeutic Barriers in Relapsed Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma remains a therapeutic challenge for clinicians, particularly when the disease recurs after initial methotrexate-based regimens. While chimeric antigen receptor T-cell therapy and bispecific antibodies have transformed the management of systemic large B-cell lymphomas, their utility in primary brain malignancies is often limited by the blood-brain barrier (the physiological boundary that prevents many systemic drugs from entering the brain parenchyma) [1, 2]. Approximately 30% to 40% of patients with aggressive B-cell malignancies experience relapsed or refractory disease, and those with central nervous system involvement face a particularly difficult prognosis due to restricted drug delivery [3, 4]. Current guidelines emphasize the need for agents that can achieve therapeutic concentrations within the central nervous system while maintaining a manageable safety profile [1, 2]. A multicenter real-world analysis now provides data on the clinical activity and pharmacology of glofitamab, a CD20xCD3 bispecific antibody, in this difficult-to-treat population.

Clinical Efficacy and Survival Outcomes

The multicenter real-world analysis evaluated the clinical activity of glofitamab monotherapy in a cohort of 16 adults with relapsed or refractory primary central nervous system lymphoma. These patients, who had failed prior lines of therapy, received the CD20xCD3 bispecific antibody (an engineered protein that simultaneously binds to CD20 on malignant B-cells and CD3 on T-cells, directing a localized immune attack against the tumor). The researchers reported that glofitamab monotherapy achieved an interim overall response rate of 75%, indicating that three-quarters of the participants experienced a measurable reduction in tumor burden. Furthermore, the complete response rate was 50%, with half of the treated patients showing no evidence of disease on follow-up imaging. Long-term outcomes in this heavily pretreated population demonstrated a median progression-free survival of 15.4 months, while the median overall survival was not reached during the study period. For several participants, glofitamab served a specific clinical role as a bridge to definitive consolidation therapies. The drug was used to reduce tumor volume and stabilize the disease before patients proceeded to chimeric antigen receptor T-cell therapy (the infusion of genetically modified autologous T-cells) or autologous stem cell transplantation (the infusion of a patient's own healthy stem cells following high-dose chemotherapy). For the practicing oncologist, this bridging strategy highlights a practical pathway to stabilize aggressive central nervous system disease, allowing more patients to reach potentially curative secondary interventions.

Pharmacokinetics and Central Nervous System Penetration

A primary challenge in managing primary central nervous system lymphoma is the blood-brain barrier, a highly selective semipermeable border that often prevents large therapeutic molecules from reaching effective concentrations within the brain parenchyma. To determine if glofitamab could overcome this physiological hurdle, the researchers conducted a pharmacokinetic analysis using paired plasma and cerebrospinal fluid (the clear fluid surrounding the brain and spinal cord) samples. The study confirmed that glofitamab was detectable in the cerebrospinal fluid of 60% of patients, providing direct evidence that this bispecific antibody can successfully traverse the blood-brain barrier in a majority of treated individuals. The researchers further quantified this drug delivery by calculating the relationship between systemic and central nervous system concentrations, revealing that the cerebrospinal fluid to plasma ratio of glofitamab reached up to 0.44%. Although this ratio indicates that central nervous system concentrations are a small fraction of those found in the systemic circulation, the levels were sufficient to correlate with the high response rates observed in the cohort. Clinically, these pharmacological findings demonstrate that even modest penetration of a bispecific antibody can facilitate the necessary T-cell engagement required to target malignant B-cells within the brain, offering a viable systemic administration route for central nervous system disease.

Molecular Monitoring via Circulating Tumor DNA

Beyond radiographic imaging, the researchers utilized serial cerebrospinal fluid circulating tumor DNA profiling (the analysis of small fragments of cancer-derived genetic material shed into the fluid surrounding the brain) to monitor treatment response at a molecular level. This liquid biopsy approach allowed for a more granular assessment of disease burden during glofitamab monotherapy than traditional imaging alone. The study found that early molecular clearance of circulating tumor DNA was associated with radiographic response, suggesting that a rapid reduction in detectable tumor DNA serves as a reliable indicator of therapeutic efficacy. For clinicians, this correlation provides a potential tool for the early identification of patients who are responding to the bispecific antibody before structural changes are fully evident on magnetic resonance imaging. The longitudinal data also highlighted the prognostic value of persistent or re-emergent circulating tumor DNA, which the researchers found preceded clinical progression in the study cohort. This molecular signal often appeared before new lesions or disease growth could be detected by standard neuroimaging, potentially offering a critical window for early clinical intervention. Additionally, the researchers examined chimeric antigen receptor T-cell kinetics (the expansion, persistence, and decline of engineered immune cells) in patients receiving consolidation treatment. These kinetic profiles underscore the importance of rigorous molecular monitoring when sequencing potent immunotherapies in the relapsed primary central nervous system lymphoma population.

Safety Profile and Neurotoxicity Risks

The safety profile of glofitamab monotherapy in the 16 adults with relapsed or refractory primary central nervous system lymphoma was characterized as manageable. Throughout the treatment period, most adverse events during glofitamab monotherapy were Grade 1 to 2, representing mild to moderate toxicities that did not require intensive intervention. This baseline safety data is particularly relevant for clinicians managing patients who may already be debilitated by prior lines of chemotherapy or the neurological burden of the lymphoma itself. Despite the generally low-grade nature of most side effects, severe neurological complications were observed in a subset of the cohort. Specifically, two patients (11%) experienced Grade 3 or higher neurotoxicity, a classification denoting severe or medically significant neurological impairment. These patients recovered after corticosteroid treatment, suggesting that while high-grade neurotoxicity is a risk, it remains responsive to standard anti-inflammatory management protocols. For the practicing oncologist, this highlights the necessity of vigilant monitoring for neurological changes and the prompt initiation of steroids when severe symptoms emerge. A more critical safety concern arose during the sequencing of therapies, particularly when glofitamab was used as a bridge to other immunotherapies. The study found that two additional patients developed fatal immune effector cell-associated neurotoxicity syndrome (a severe inflammatory response in the central nervous system characterized by cognitive dysfunction, altered consciousness, or cerebral edema) following chimeric antigen receptor T-cell consolidation. These fatal outcomes occurred after the transition from glofitamab to cellular therapy, indicating that while the bispecific antibody itself has a manageable safety profile as a single agent, the risk of lethal neurotoxicity may increase significantly when it is followed by other potent immune-activating treatments.

References

1. Thiéblemont C, Silva MGD, Leppä S, et al. Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere. 2025. doi:10.1002/hem3.70207

2. Chaganti S, Fox CP, Maybury B, et al. Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline. British Journal of Haematology. 2025. doi:10.1111/bjh.20129

3. Sesques P, Manson G, Dubois S, et al. Large B-cell lymphoma: The LYSA pragmatic guidelines. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.116070

4. Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01521-5